Physician profile
Komal Abbas
NPI 1811419914
$2,239.18
in general payments reported to CMS, 2019-2025
14 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $415 · 2022: $18.62 · 2023: $166 · 2024: $101 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $770.94 | 2019-2025 | Tryptyr, Precision 1, Precision7 |
| Coopervision INC. | $485.74 | 2019-2025 | Onefit Contact Lens, Myday Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb Americas INC. | $310.92 | 2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.67 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $92.63 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $75.49 | 2019 | |
| Sun Pharmaceutical Industries INC. | $72.81 | 2025 | |
| Ivantis, INC | $71.42 | 2020 | |
| Glaukos Corporation | $71.26 | 2019-2023 | Photrexa Cross-Linking Kit |
| Alcon Research LLC | $60.61 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $58.15 | 2023-2025 | Acuvue |
| Dompe US, INC. | $36.91 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $17.39 | 2025 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.